Christian Holm Hansen

Christian Holm Hansen er statistiker og epidemiolog i Afdeling for Infektionsepidemiologi og Forebyggelse ved Statens Serum Institut (SSI) og Associate Professor ved London School of Hygiene and Tropical Medicine (LSHTM) i UK.

På SSI arbejder Christian hovedsageligt med covid-19-epidemiologi, og har været involveret i adskillige store populationsstudier med det formål at estimere beskyttelsesniveau og varighed af covid-19-vaccinationerne samt immunbeskyttelse efter tidligere infektion mod reinfektion med SARS-CoV-2. Han er desuden medlem af SSI's Forum for Global Sundhed og bidrager til forskning i HIV-forebyggelse og infektionssygdomme i Afrika syd for Sahara, herunder randomised controlled trials af vaccinekandidater.

Interesseområder: infektionssygdomsepidemiologi, global sundhed, clinical trials, statistisk modellering.

Se også profile at LSHTM

Google Scholar

Udvalgte publikationer

Hansen CH, Lassauniere R, Rasmussen M, Moustsen-Helms IR, Valentiner-Branth P. Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted Vaccines Against COVID-19-associated Hospitalisation and Death: a Danish Nationwide Register-based Cohort Study. 2025, Lancet Infect Dis. LINK

Bahemuka U, Hall L, Okimat P, Abaasa A, Hansen CH, Mayaud P. Impact of the dual rapid diagnostic test for HIV and syphilis among pregnant women: a before and after health centre-based study in Central Uganda (2018-2019). 2025 Int J Infect Dis. LINK

Anywaine Z, Wright D, Warimwe GM, Kaleebu P, Elliott A, Hansen CH. Rift Valley fever sero-prevalence and risk factors among human populations in Uganda’s cattle corridor: a cross-sectional study. 2025, BMJ Public Health. LINK

Anywaine Z, Serwanga J, Mustapher GA, Abaasa A, Wright D et al. Safety, tolerability, and immunogenicity of the ChAdOx1RVF vaccine against Rift Valley fever among healthy adults in Uganda: a randomised, placebo-controlled, dose-escalation clinical trial. 2025, Lancet Infect Dis. LINK

Borges AH, Russell M, Tait D, Scriba TJ, Nemes E et al. A phase 2b, double-blind, randomised, placebo-controlled study to evaluate the immunogenicity, safety and efficacy of the vaccine H56:IC31® in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis. Lancet Infect Dis. 25(7):751–763 LINK

Kansiime S, Hansen CH, Bern H, Fox J, Dunn D, et al. Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm. 2025, HIV Res Clin Pract. 2025 Dec;26(1):2513684. LINK

Moustsen-Helms IR, Bager P, Larsen TG, …, Hansen CH. Relative vaccine protection, disease severity and symptoms associated with the SARS-CoV-2 Omicron subvariant BA.2.86 and descendant JN.1: A Danish nationwide register-based study. 2024, Lancet Infect Dis. 24: 964–73 LINK

Hansen CH, Moustsen-Helms IR, Rasmussen M, Søborg B, Ullum H, Valentiner-Branth P. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study. 2024, Lancet Infect Dis., Vol. 24(2), e73-e74. LINK

Fabian J, Kalyesubula R, Mkandawire J, Hansen CH, Nitsch D et al. Measurement of kidney function in Malawi, South Africa, and Uganda: a multicentre cohort study. 2022, Lancet Global Health; 10: e1159-e1169 LINK

Hansen CH, Friis NU, Bager P, Stegger M, Fonager J et al. Risk of Reinfection, Vaccine Protection, and Severity of Infection with the BA.5 Omicron Subvariant: A Danish Nation-Wide Population-Based Study. 2022, Lancet Infect Dis 2023;23: 167–76 LINK

Gram MA, Emborg H-D, Schelde AB, Friis NU, …, Hansen CH. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. 2022, PLoS Medicine 19(9):e1003992 LINK

Michlmayr D, Hansen CH, Gubbels SM, Valentiner-Branth P, Bager P et al. Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. Lancet Regional Health Europe. 2022 Sep;20:100452. LINK

Fabian J, Kalyesubula R, Mkandawire J, Hansen CH, Nitsch D et al. Measurement of kidney function in Malawi, South Africa, and Uganda: a multicentre cohort study. 2022, Lancet Global Health; 10: e1159-e1169 LINK

Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. 2021, The Lancet, Vol.397 (10280), 1204-1212. LINK